Form 4: Aprea Therapeutics CEO Oren Gilad Acquires Shares and Warrants

Aprea Therapeutics' CEO, Oren Gilad, recently purchased 2,000 shares of common stock and acquired Tranche A and B warrants.

Summary

• On March 13, 2024, Oren Gilad, the President and CEO of Aprea Therapeutics, purchased 2,000 shares of the company's common stock at a price of $7.29 per share.
• Gilad also acquired 1,000 Tranche A warrants and 1,000 Tranche B warrants.
• Following these transactions, Gilad directly owns 324,770 shares of Aprea Therapeutics' common stock, along with 1,000 Tranche A warrants and 1,000 Tranche B warrants.
• The Tranche A warrants have an exercise price of $7.29 per share and expire on March 13, 2027, with potential for earlier termination under certain conditions.
• The Tranche B warrants have an exercise price of $9.1125 per share and expire on March 13, 2029, also with potential for earlier termination under certain conditions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive signal, but it's a relatively small transaction. The warrants add a layer of complexity but don't drastically alter the overall sentiment.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The warrants' early termination clauses are tied to the announcement of Phase 2 doses for ATRN-119 and APR-1051, and the stock's VWAP reaching certain thresholds, suggesting these are key milestones for the company.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects. This Form 4 filing is a routine disclosure required by the SEC.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Next Steps

• Investors will likely monitor the progress of ATRN-119 and APR-1051, as the achievement of Phase 2 dose recommendations and stock price targets could trigger the early termination of the warrants.

Key Dates